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Abstract  1 
Background  2 
Lung cancer is the leading cause of cancer mortality in Wales. We conducted a before- and after- 3 
study to evaluate the impact of a four-week mass media campaign on awareness, presentation 4 
behaviour and lung cancer outcomes. 5 
Methods 6 
Population-representative samples were surveyed for cough symptom recall/recognition and worry 7 
about wasting doctors’ time pre-campaign (June 2016; n=1,001) and post-campaign (September 8 
2016; n=1,013). GP cough symptom visits, urgent suspected cancer (USC) referrals, GP-ordered 9 
radiology, new lung cancer diagnoses and stage at diagnosis were compared using routine data 10 
during the campaign (July-August 2016) and corresponding control (July-August 2015) periods.  11 
Results  12 
Increased cough symptom recall (p<0.001), recognition (p<0.001) and decreased worry (p<0.001) 13 
were observed. GP visits for cough increased by 29% in the target 50+ age-group during the 14 
campaign (p<0.001) and GP-ordered chest X-rays increased by 23% (p<0.001). There was no 15 
statistically significant change in USC referrals (p=0.82), new (p=0.70) or early stage (p=0.27) 16 
diagnoses, or in routes to diagnosis.  17 
Conclusion 18 
Symptom awareness, presentation and GP-ordered chest x-rays increased during the campaign, but 19 
did not translate into increased USC referrals or clinical outcomes changes. Short campaign duration 20 
and follow up, and the small number of new lung cancer cases observed may have hampered 21 
detection effects.  22 
 23 
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Background  1 
Lung cancer has the highest mortality of all cancer types, accounting for a fifth of all cancer deaths 2 
worldwide1. Lung cancer survival outcomes in the UK are amongst the worst of comparable high-3 
income countries2. High incidence and poor long-term survival mean that mortality rates are high3, 4 
particularly in areas of high socioeconomic deprivation. Lung cancer incidence rises steeply with 5 
increasing deprivation and the survival inequality gap is widening4. Delayed symptomatic 6 
presentation to a primary care physician and delays within and across primary and secondary care 7 
contribute to diagnosis of lung cancer in the later stages of disease5-7. The possibility of curative 8 
treatment decreases with later-stage disease diagnosis; in the UK, less than a fifth of patients are 9 
eligible for surgical resection, in turn influencing outcomes6,8.  10 
In the absence of routine lung cancer screening, early lung cancer diagnosis relies on prompt patient 11 
presentation and GP referral with symptoms indicative of lung cancer. Low public awareness of lung 12 
cancer symptoms is one possible barrier to prompt symptomatic presentation, contributing to 13 
normalisation and delay in reporting symptoms9-13. Interventions are therefore required to raise lung 14 
cancer symptom awareness and reduce barriers to early presentation to expedite diagnosis14. 15 
However, evidence of the impact of symptom awareness campaigns is limited15. In 2008, the 16 
National Awareness and Early Diagnosis Initiative was formed in England with the aim of improving 17 
cancer outcomes through earlier diagnosis16. Consequently, a national programme of cancer 18 
awareness activity was developed, including a focus on lung cancer, and there were also pockets of 19 
local activity. Evaluations of these interventions have suggested that these activities might have 20 
increased the number of lung cancers diagnosed at an earlier stage17-19. However, to date, there is 21 
little evidence regarding the effectiveness of mass-media symptom awareness campaigns18 that 22 
have been adapted and implemented in different geographical settings and demographic contexts.  23 
 24 
In response to poor lung cancer outcomes in Wales, and with evidence from the English Be Clear on 25 
Cancer (BCOC) campaign suggesting stage shift18, the Welsh BCOC mass-media campaign was 26 
launched in 2016.  The campaign was designed to increase public awareness of cough as a symptom 27 
of cancer and encourage adults over 50 years of age, especially among lower socioeconomic groups, 28 
to visit their GP if they had cough symptoms for three weeks or more. Cough is the most common 29 
presenting lung cancer symptom, and with reported low public awareness of cough as a cancer 30 
symptom, persistent cough was selected as the primary target symptom for the campaign9, 20-24.  31 
To evaluate the impact of the Welsh BCOC campaign, we conducted a quasi-experimental study with 32 
a before- and after- design, utilising survey responses and routinely collected data. Population based 33 
survey data to assess lung cancer symptom awareness and worry about wasting GP time as a 34 
perceived barrier to medical help seeking were compared one month before the campaign (pre 35 
campaign period; June 2016) to one month after the campaign (post-campaign period; September 36 
2016). Routine data including symptomatic presentations, primary care referrals, diagnostic testing 37 
and cancer diagnoses were compared in the campaign time period (July-August 2016) to the 38 
equivalent time period in 2015 (control period).  39 
Methods 40 
The STROBE statement (strengthening the reporting of observational studies in epidemiology) 41 
guided reporting (Supplementary File 1).  42 
Intervention 43 
To inform the campaign, six focus groups (four groups of current or former smokers, two groups of 44 
never smokers, total n=48 participants) were undertaken in Wales during August 2015 to gauge 45 
audience receptiveness to existing lung cancer campaign materials from England, Scotland and 46 
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Northern Ireland, who had already run national public awareness campaigns. Following minor 1 
adaptations from the English campaign, the Welsh lung cancer awareness campaign was launched in 2 
2016 with the strapline “If you’ve had a cough for three weeks or more, tell your doctor” in both 3 
Welsh and English (Supplementary Files 2-5; https://www.cancerresearchuk.org/health-4 
professional/awareness-and-prevention/be-clear-on-cancer/lung-cancer-awareness-campaign-5 
wales).  6 
Campaign messages were disseminated between 11th July and 11th August 2016 on television (S4C 7 
and ITV), online, bus and radio adverts, and on posters in pharmacies and on buses. The TV advert 8 
was intentionally crafted to appeal to older adults and people from lower socioeconomic (C2DE) 9 
groups. Where possible, campaign elements were targeted to reach more deprived groups (i.e. 10 
television scheduling, locations for advertising). Primary care engagement in advance of the 11 
campaign included circulating health care professional briefing materials with details of the 12 
campaign to health boards and primary care networks (https://www.cancerresearchuk.org/health-13 
professional/awareness-and-prevention/be-clear-on-cancer/lung-cancer-awareness-campaign-14 
wales#BCOC_Lung_Wales_Essential0). The first national BCOC respiratory campaign ran in England 15 
during the same time period as the Welsh lung BCOC campaign (July-October 2016). This also 16 
included three week cough messaging utilised in previous English lung cancer campaigns, which was 17 
promoted via a range of channels including digital television with reach into Wales. This alignment of 18 
campaign timing aimed to increase the dissemination of the three week cough message in Wales. 19 
English BCOC lung cancer campaigns that had run prior to 2016 had also utilised media channels that 20 
had reached into Wales, providing opportunity for Welsh audiences to have heard the three week 21 
cough message in advance of the dedicated Welsh national activity.  22 
Participants and procedures 23 
Survey data 24 
Pre-campaign (June 2016) and post-campaign (September 2016) population samples were surveyed 25 
by Beaufort Research, a market research company. Survey questions were informed by the Cancer 26 
Awareness Measure25 and previous campaign evaluation tracking in England, and were included as 27 
part of an omnibus survey carried out with a representative sample of the Welsh population (aged 28 
16+) using face-to-face interviews.  29 
Survey questions included gender, age, social group, number of children in the household and area 30 
of residence (Cardiff and South East Wales, Mid/West Wales, North Wales, Valleys and West/South 31 
Wales). Each respondent was allocated to ‘ABC1’ or ‘C2DE’ based on their responses to a range of 32 
profiling questions for social group, with ABC1 reflecting less deprived, and C2DE reflecting more 33 
deprived groups. Lung symptom awareness was measured using recall (“There are many warning 34 
signs and symptoms of lung cancer. Please name as many as you are aware of”) and prompted 35 
recognition questions (“I’m now going to list some symptoms that may or may not be warning signs 36 
for lung cancer. For each one, can you tell me the extent to which you think it is a warning sign for 37 
lung cancer?”). For the recognition question, the symptoms listed were: a cough for three weeks or 38 
more that does not go away, breathlessness, coughing up blood, a persistent pain in your chest or 39 
shoulder, losing weight for no obvious reason and a cough that got worse or changes. Response 40 
options were: definitely a warning sign, probably a warning sign, probably not a warning sign, 41 
definitely not a warning sign and don’t know. Responses were dichotomised as definitely a warning 42 
sign/probably a warning sign versus Definitely not a warning sign/probably not a warning sign. ‘Don’t 43 
know’ responses were not included in the regression analysis. To align with the focus of the 44 
campaign, data are reported for recognition/recall of cough symptom. 45 
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Worry about wasting the doctor’s time was measured using the question “I’m going to read you a 1 
statement that is sometimes made about lung cancer. Can you please tell me how much you agree or 2 
disagree with it – that is whether you strongly agree, agree, disagree or strongly disagree. If I had a 3 
cough, I would be worried about wasting the GP/doctor’s time”. Response options were 4 
dichotomised as strongly agree/agree versus strongly disagree/disagree. 5 
Routine data 6 
Relevant routine data were sourced for pre-campaign (May and June), campaign (July and August) 7 
and post-campaign (September and October) periods in 2016, and the same periods in 2015. For the 8 
main comparison, the campaign period (July and August 2016) was compared to the comparable 9 
time period in the previous year (control period; July and August 2015). Health care and clinical 10 
outcomes included: 11 
i. Primary care presentations. Anonymised counts of visits to GP practices for the cough symptom 12 
were identified using defined Read codes extracted from the Securely Anonymised Information 13 
Linkage (SAIL) databank. Counts were extracted for any patient registered with a GP practice in 14 
Wales using GP data within SAIL for all time points. The number of visits per practice/per week for 15 
the target cough symptom and control symptoms including neck pain, knee pain, shoulder pain and 16 
urinary tract infections in people aged 50 years and older was calculated for all time points.  17 
ii. Urgent suspected cancer (USC) referrals. USC referrals (patients with suspected lung cancer who 18 
are urgently referred from primary care to a specialist, and who are confirmed as urgent by the 19 
specialist) were received from the Welsh Government both at all-Wales and local health board 20 
(hospital) level. Conversion rates were calculated using the USC referral data received from Welsh 21 
Government. To calculate the conversion rate (the proportion of urgent referrals that resulted in a 22 
lung cancer diagnosis), the number of lung cancers diagnosed as a result of an urgent suspected 23 
cancer referral was divided by the number of USC referrals.  24 
iii. Radiology requests. The number of chest x-rays and chest CT scans carried out in each month 25 
(including tests with or without abdomen) was extracted for each health board from their systems. 26 
The aggregated data for Wales was used to calculate a count for all time points split by GP-referred 27 
and ‘all-referred’ tests. GP-referred tests were adjusted for working days because most GP surgeries 28 
are open Monday-Friday, while ‘all-referred’ tests could include referrals from other pathways that 29 
can occur on weekends. 30 
iv. Number of new lung cancers diagnosed, stage, source of referral. Lung cancer (ICD10 codes C33-31 
C34) incidence data for non-small cell and small cell were extracted from the Cancer Network 32 
Information System Cymru (CaNISC) electronic patient records, and split by month and year. Non-33 
small cell lung cancer cases included histological, cytological or clinical diagnoses. The number of 34 
lung cancer cases diagnosed for the 2016 time points was compared to the number of cases 35 
diagnosed in the corresponding time periods in 2015. Staging data for small cell and non-small cell 36 
lung cancers were combined and grouped into early stage (stages I and II) and late stage (III and IV). 37 
The proportion of early and late stage cancers for known stages were calculated. The source of 38 
referral was extracted for patients diagnosed with lung cancer for the 2016 and 2015 time periods. 39 
Numbers and percentages of patients diagnosed with lung cancer following emergency attendance, 40 
accident and emergency admission, GP referral, and consultant referral were identified from the 41 
CaNISC records. Diagnosis following referral after emergency attendance and accident and 42 
emergency admission were combined to ‘emergency department referral’.  43 
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v. First treatment received and performance status. The number of lung cancer cases in each 1 
treatment category were extracted for the 2016 time periods and the corresponding time periods in 2 
2015. The proportion of all lung cancer cases by treatment group was compared across the 2015 and 3 
2016 time points. Performance status data for all lung cancer cases diagnosed in the corresponding 4 
2015 and 2016 time periods was extracted, according to the following categories: 0 (able to carry 5 
out normal activity without restriction), 1 (restricted in physically strenuous activity but ambulatory 6 
and able to carry out light work), 2 (ambulatory and capable of all self-care but unable to carry out 7 
any work up to about >50% of waking hours), 3 (capable of only limited self-care, confined to bed or 8 
chair >50% of waking hours), 4 (completely disabled, cannot carry out any self-care, totally confined 9 
to bed or chair), and unknown. Proportions of lung cancer cases by performance status category 10 
were compared across the 2015 control time period and 2016 campaign period.  11 
Statistical analysis 12 
Multivariable logistic regression was used to investigate pre- to post- campaign differences in cough 13 
recall/recognition and worry about wasting the GP’s time, adjusting for demographic differences 14 
between survey samples. Survey data were weighted by age group within gender within Local 15 
Authority grouping, to be representative of the Welsh population. Interaction terms were used to 16 
test differences between social groups in awareness over time.  17 
For the main comparison of the campaign period (July-August 2016) and the equivalent control 18 
period in the previous year (July-August 2015), changes in clinical outcomes were assessed using the 19 
two-sample test of proportions or the likelihood ratio tests for counts. The number of days was 20 
adjusted due to differences in the number of GP working days in each time period. The significance 21 
level was set at p<0.001 to adjust for multiple testing.  22 
Results 23 
Survey sample characteristics 24 
Sample characteristics are presented in Table 1. The pre-campaign (n=1,011) and post-campaign 25 
samples (n=1,013) were primarily female (pre-campaign 56.7%; post-campaign 53.1%), from the less 26 
affluent social group C2DE (pre-campaign 54.6%; post-campaign 53.8%), aged 45 years or over (pre-27 
campaign 59.4%; post-campaign 60.7%) and resident in Cardiff/South East Wales (pre-campaign 28 
26.2%; post-campaign 26.5%).  29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
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Table 1. Demographic characteristics of survey sample pre- and post-campaign  1 
 Pre-campaign (June 
2016; n=1011)  
Post-campaign (Sept 
2016; n=1013) 
N % N % 
Gender      
Male  438 43.3 475 46.9 
Female  573 56.7 538 53.1 
Age      
16-24 127 12.6 89 8.8 
25-34 154 15.2 168 16.6 
35-44 130 12.9 141 13.9 
45-54 174 17.2 153 15.1 
55-64 138 13.7 157 15.5 
65 and over 288 28.5 305 30.1 
Social group (SES)      
AB (most affluent) 144 14.2 176 17.4 
C1 315 31.2 291 28.7 
C2 194 19.2 188 18.6 
DE (most deprived) 358 35.4 356 35.2 
Area of residence      
Cardiff/South East Wales  265 26.2 268 26.5 
Mid/West Wales  162 16.0 166 16.4 
North Wales 208 20.6 230 22.7 
Valleys  174 17.2 181 17.9 
West/South Wales 202 20.0 168 16.6 
Children in household     
Yes   323 31.9 344 34 
No  688 68.1 669 66 
 2 
Cough symptom awareness and worry about wasting the doctor’s time 3 
As shown in Table 2, there was a statistically significant 13.3% increase in recall (p<0.001) and 4.4% 4 
increase in recognition (p<0.001) of the cough symptom pre- to post-campaign. There was a 5 
statistically significant 7.5% increase in recall of shortness of breath (p<0.001) and 11.7% reduction 6 
in the number of people who could not recall any symptoms of lung cancer (p<0.001) pre-to-post 7 
campaign. The relationship between social group and recognition of the cough symptom was not 8 
significant (p=0.370 for the interaction term).  9 
There was a statistically significant 6.4% reduction in worry about wasting the GP’s time pre- to post-10 
campaign (p<0.001). There was a statistically significant 10% decline in worry about wasting GP time 11 
for C2DE (the most deprived group) pre- to post-campaign (p=0.001), but a non-statistically 12 
significant 1.6% decline for ABC1 (the more affluent group) (p=0.33). 13 
 14 
 15 
 16 
 17 
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Table 2. Public awareness and barriers to help seeking pre- and post-campaign survey results  1 
Survey question  Pre-campaign 
(June 2016; 
n=1011) 
Post-campaign 
(Sept 2016; 
n=1013) 
% 
change  
p-value 
Symptom recall 
Cough/coughing 27.5% 40.8% 13.3% <0.001 
Persistent/ long lasting/ bad cough  14.2% 15.4% 1.2% 0.26 
Shortness of breath/ bad     
chest/difficulty breathing 
29.7% 37.2% 7.5% <0.001 
    Coughing up blood/ blood in mouth      
    or mucus   
22.5% 18.1% -4.4% 0.05 
    Don’t know/none 31.4% 19.7% -11.7% <0.001 
Symptom recognition 
A cough for three weeks or more  
that does not go away 
82.2% 86.6% 4.4% <0.001 
Breathlessness 83.6% 85.9% 2.3% 0.39 
Coughing up blood 95.5% 93.3% -2.2% 0.02 
A persistent pain in your chest or  
shoulder 
68.9% 67.2% -1.7% 0.18 
   Losing weight for no obvious reason  78.5% 74.7% -3.8% 0.02 
A cough that has got worse or  
changes 
87.1% 88.9% 1.8% 0.32 
Recognition of three-week cough by social group  
ABC1 (most affluent)  80.5% 83.9% 3.4% 0.16 
C2DE (most deprived)  86.3% 87.2% 0.9% 0.02 
Worry about wasting GP time  
    ABC1 (most affluent) 47.9% 46.3% -1.6% 0.33 
C2DE (most deprived) 50.1% 40.1% -10.0% <0.001 
Total  49.2% 42.8% -6.4% <0.001 
Results in bold indicate a statistically significant change between 2015 and 2016 2 
GP presentations  3 
The number of GP visits for cough symptoms increased significantly between the control and 4 
campaign period in all age groups apart from 10-19 year olds (Table 3). The total number of people 5 
of all ages presenting to their GP with a cough during the 2016 campaign period increased 6 
significantly by 21.4% (p<0.001) compared to the corresponding control period in 2015. In the target 7 
age group of people aged 50 years and over, there was a statistically significant 24.3% increase 8 
(p<0.001) in the number of visits to a GP for cough during 2016 compared to the equivalent 2015 9 
control period.   10 
Among the target over 50s age group, the number of presentations with a cough increased from 6.0 11 
per GP practice per week during 2015 to 7.7 per GP practice per week during the campaign period in 12 
2016, equivalent to a statistically significant increase of 28.9% (p<0.001). In the same time period,  13 
there was no significant increase in the number of GP presentations among the over 50 age group 14 
for each of the four control symptoms of urinary tract infection (p=0.77), neck pain (p=0.26), 15 
shoulder pain (p=0.23) or knee pain (p=0.37) (Table 3).  16 
 17 
 18 
 19 
 9 
 
Table 3. Number of cough presentations adjusted weekly rate of GP presentations for cough and 1 
four control symptoms in patients aged 50 years and cough presentations by age group  2 
 2015; n 2016; n Change (n) % change  P-value 
Number of presentations per practice per week in patients over the age of 50 (adjusted*) 
Cough  
Pre-campaign 7.9 7.6 -0.3 -3.1  
Campaign  6.0 7.7 1.7 28.9 <0.001 
Post-campaign 8.1 8.3 0.2 2.1  
Urinary Tract Infection 
Pre-campaign 1.0 1.0 0.0 1.1  
Campaign  1.0 1.1 0.1 4.5 0.77 
Post-campaign 1.1 1.1 0.1 6.3  
Neck Pain 
Pre-campaign 1.0 1.1 0.1 3.0  
Campaign  1.0 1.0 0.0 0.7 0.26 
Post-campaign 1.1 1.1 0.0 -2.2  
Shoulder Pain 
Pre-campaign 0.1 0.1 0.0 5.9  
Campaign  0.1 0.1 0.0 14.7 0.23 
Post-campaign 0.1 0.1 0.0 0.8  
Knee Pain 
Pre-campaign 3.2 3.2 0.0 2.1  
Campaign  2.9 3.1 0.2 5.1 0.37 
Post-campaign 2.9 3.0 0.1 1.7  
Number of presentations for cough symptom during the campaign period (July and August 2016) 
and corresponding time period in the previous year (July-August 2015) by age group  
Age group      
0-9 5745  6612  867 15.1 <0.001 
10-19 1870  2061  191 10.2 0.002 
20-29 2112  2561  449 21.3 <0.001 
30-39 2155  2747  592 27.5 <0.001 
40-49 3075  3673  598 19.4 <0.001 
50-59 4197  5324  1127 26.9 <0.001 
60-69 5374  6605  1231 22.9 <0.001 
70-79 4676  5900  1224 26.2 <0.001 
80+ 3050  3678  628 20.6 <0.001 
Total aged 50+  17297  21507  4210 24.3 <0.001 
Total all ages  32254  39161  6907 21.4 <0.001 
*adjusted for working days. Results in bold indicate a statistically significant change between 2015 and 2016 3 
 4 
Urgent suspected cancer referrals and conversion rate 5 
 6 
There was a non-significant 1.2% reduction (p=0.82) in the total number of USC referrals for 7 
suspected lung cancer, and a non-significant 1.4% reduction (p=0.56) in the number of USC referrals 8 
resulting in a lung cancer diagnosis (conversion rate) between the 2016 campaign period and the 9 
equivalent time period in 2015 (Table 4).   10 
 11 
 10 
 
Table 4. Urgent suspected lung cancer referrals and conversion rate  1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
*adjusted for working days.  10 
Radiology requests 11 
A statistically significant increase of 23.4% in GP-referred chest x-rays (p<0.001), and 8.1% increase 12 
in chest x-rays from all referral sources (p<0.001) was reported in the 2016 campaign period 13 
compared to the equivalent time period in 2015 (Table 5) 14 
There was a non-statistically significant 9.6% increase in GP-referred chest CT scans in the 2016 15 
campaign period compared to the equivalent time period in 2015 (p=0.06). There was a statistically 16 
significant 10.1% increase in the number of chest CT scans from all referral sources (p<0.001) in the 17 
2016 campaign period compared to the equivalent time period in 2015 (Table 5). 18 
Table 5. Number of chest x-rays and chest CT scans conducted  19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
*adjusted for working days. Results in bold indicate a statistically significant change between 2015 and 2016 32 
Number and stage of new lung cancers diagnosed 33 
There were no statistically significant changes in the number of new diagnoses of non-small cell lung 34 
cancer (p=0.34), small cell lung cancer (p=0.38) or the total number of new lung cancer diagnoses 35 
(p=0.70) ) in the 2016 campaign period compared to the equivalent time period in 2015 (Table 6).  36 
 2015 2016 % change 
(adjusted*) 
P-value  
Urgent suspected lung cancer referrals (total, n)  
Pre-campaign 623 659 3.3  
Campaign  650 642 -1.2 0.82 
Post-campaign 581 559 -1.6  
Conversion rate (%) 
Pre-campaign 24.2% 24.9% 0.6  
Campaign  25.1% 23.7% -1.4% 0.56 
Post-campaign 22.9% 23.1% 0.2%  
 Number of tests 
(n) 
Tests per day (adjusted*)  
2015 2016 2015 2016 % 
change 
P-value  
GP referred chest X-rays 
Pre-campaign 21714 23092 529.6 549.8 3.8  
Campaign  19107 23585 444.3 548.5 23.4 <0.001 
Post-campaign 21368 23409 485.6 544.4 12.1  
All chest x-rays 
Pre-campaign 77763 79787 1896.7 1899.7 0.2  
Campaign  73690 79686 1713.7 1853.2 8.1 <0.001 
Post-campaign 77556 80912 1762.6 1881.7 6.8  
GP referred chest CT scans 
Pre-campaign 746 843 18.2 20.1 10.3  
Campaign  780 855 18.1 19.9 9.6 0.06 
Post-campaign 678 791 15.4 18.4 19.4  
All Chest CT scans  
Pre-campaign 5207 6040 127 143.8 13.2  
Campaign  5244 5775 122 134.3 10.1 <0.001 
Post-campaign 5390 5871 122.5 136.5 11.5  
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There were no statistically significant differences in staging data. There was a non-statistically 1 
significant 3.5% increase in the total number of early stage (I and II) cases of lung cancer cases 2 
(p=0.27) and a 3.5% non-significant decrease in the total number of late stage (III and IV) cases of 3 
lung cancer (p=0.27) in the 2016 campaign period compared to the equivalent time period in 2015 4 
(Table 6).  5 
Referral source of number of lung cancers diagnosed  6 
There were no statistically significant changes in the number of new lung cancer diagnoses from all 7 
referral sources. There was a non-statistically significant increase in the proportion of new lung 8 
cancer diagnoses after referral through emergency department (6.3% increase; p=0.04), referral 9 
through from an inpatient consultant (1.8% increase; p=0.22) and referral from other sources (2.4% 10 
increase; p=0.02) during the 2016 campaign to the equivalent time period in 2015 (Table 6).  11 
There was a non-statistically significant decrease in the proportion of new lung cancer diagnoses 12 
after referral through from a non-accident and emergency department consultant (7.2% decrease; 13 
p=0.02), and referral from the GP (3.3% decrease; p=0.35) during the 2016 campaign period to the 14 
equivalent time period in 2015 (Table 6).  15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
 34 
 35 
 12 
 
Table 6. Number and stage  of lung cancer patients, with diagnosis by source of referral  1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
*Small-cell and non-31 
small cell lung cancer cases combined; %’s presented as proportions of the total known cases $Statistical testing not conducted due to very small numbers 32 
 2015 
Number of cases (%) 
2016 
Number of cases (%) 
n Change p-
value 
Number of new lung cancer cases 
Non-small cell lung cancer  
Pre-campaign 324 326 2  
Campaign  348 372 24 0.34 
Post-campaign 342 318 -24  
Small-cell lung cancer  
Pre-campaign 51 47 -4  
Campaign  53 40 -13 0.38 
Post-campaign 42 39 -3  
Total 
Pre-campaign 375 373 -2  
Campaign  401 412 11 0.70 
Post-campaign 384 357 -27  
 2015 
Number of cases (%) 
2016 
Number of cases (%) 
% 
Change 
p-
value 
Stage of new lung cancer cases number and proportion of cases with known stage*  
Early (stage I and II)  
Pre-campaign 95 (25.5%) 85 (23.4%) -2.1%  
Campaign  98 (24.8%) 114 (28.3%) 3.5% 0.27 
Post-campaign 114 (30.2%) 94 (27.0%) -3.2%  
Late (stage III and IV) 
Pre-campaign 277 (74.5%) 278 (76.6%) 2.1%  
Campaign  297 (75.1%) 289 (71.7%) -3.5% 0.27 
Post-campaign 263 (69.8%) 254 (73.0%) 3.2%  
Stage unknown  
Pre-campaign 3 10   
Campaign$ 6 9   
Post-campaign 7 9   
Number and proportion of new lung cancer cases diagnosed by source of referral  
Following A&E attendance or emergency admission  
Pre-campaign 102 (27.2%) 111 (29.8%)  2.6%  
Campaign  89 (22.2%)  117 (28.5%) 6.3% 0.04 
Post-campaign 103 (26.8%)  108 (30.3%) 3.4%  
Referral from GP 
Pre-campaign 176 (46.9%)  184 (49.3%) 2.4%  
Campaign  180 (44.9%)  171 (41.6%)  -3.3% 0.35 
Post-campaign 154 (40.1%)  146 (40.9%) 0.8%  
Referral from a consultant (other than in an A&E department) 
Pre-campaign 73 (19.5%)  57 (15.3%) -4.2%  
Campaign  112 (27.9%)  85 (20.7%)  -7.2% 0.02 
Post-campaign 103 (26.8%)  77 (21.6%) -5.3%  
Referral from a consultant (from inpatients) 
Pre-campaign 13 (3.5%) 9 (2.4%) -1.1%  
Campaign  16 (4.0%) 24 (5.8%)  1.8% 0.22 
Post-campaign 11 (2.9%)  16 (4.5%) 1.6%  
Other source 
Pre-campaign 11 (2.9%) 12 (3.2%) 0.3%  
Campaign  4 (1.0%) 14 (3.4%) 2.4% 0.02 
Post-campaign 13 (3.4%) 10 (2.8%) -0.6%  
Not recorded 
Pre-campaign 0 (0%) 0 (0%) 0%  
Campaign  0 (0%) 1 (0.2%) 0.2%  
Post-campaign 0 (0%) 0 (0%) 0%  
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First treatment received and performance status of lung cancers diagnosed 1 
For all forms of treatment including surgical resection, there was no statistically significant 2 
difference during the 2016 campaign period to the equivalent time period in 2015 (Supplementary 3 
File 6). There were no statistically significant changes in all performance status categories for new 4 
lung cancer patients during the 2016 campaign to the equivalent time period in 2015 5 
(Supplementary File 7). 6 
Discussion  7 
We evaluated the impact of the first nationwide mass-media lung cancer symptom awareness 8 
campaign to be conducted in Wales. The campaign was successful in raising public awareness of 9 
cough as a symptom of lung cancer and in reducing barriers to symptomatic presentation. A greater 10 
reduction in worry about wasting GP time was observed after the campaign, especially among 11 
socioeconomically deprived groups. Behavioural changes were observed during the campaign, with 12 
an increase in the number of patients presenting to their GP with a cough symptom for the target 13 
over 50s target group. Although GP-ordered chest x-rays increased during the campaign, this did not 14 
extend to USC referrals or the number and stage distribution of new lung cancer diagnoses.  15 
The first national BCOC lung cancer campaign in England, involving a four-week regional pilot in the 16 
central TV region in 2011 and eight-week national mass media campaign in 2012, reported increased 17 
symptom awareness, primary care cough symptom presentations and GP requested chest x-rays17,18. 18 
A subsequent community-based lung cancer awareness campaign run over an extended period of 19 
time, combining public awareness activities with open-access walk-in chest x-ray for those with 20 
symptoms that could indicate lung cancer and GP education19 also reported improved lung cancer 21 
outcomes including a highly significant stage shift and higher treatment rates. We found a significant 22 
increase in the number of GP presentations with a cough symptom and GP-ordered chest X-ray 23 
requests. However, when comparing the campaign time period in 2015 to the pre- and post-24 
campaign time period data for 2015 (Tables 3 and 5), the reported number of cough symptom 25 
presentations and GP-ordered chest X-rays are substantially lower. The lower number of cough 26 
presentations and radiology requests in the 2015 campaign period may either be lower by chance 27 
(thus artificially inflating our findings), or reflect the time of year when the 2016 campaign was run 28 
(July-August) outside of flu season.  29 
We found no impact of the Welsh BCOC campaign on USC referrals or other clinical outcomes. Our 30 
findings likely reflect the need for higher-intensity briefings for health-professionals with 31 
information about campaign activities and symptoms for referral. Further, it is possible that despite 32 
the increase in cough presentations, system and access barriers from primary care to secondary care 33 
in Wales may have led to no increase in the proportion of lung cancer cases diagnosed through the 34 
GP referral route, reflecting the need for service re-design.  35 
The current campaign was designed to target adults over the age of 50, particularly from C2DE 36 
audiences. However, public-facing materials did not display age-related risk information to maintain 37 
simple campaign messaging. Campaign developers selected actors for the campaign materials to 38 
implicitly reinforce age. It is possible that without explicit advice on age-related risk, younger and 39 
lower risk individuals presented to primary care with symptoms, impacting USC referrals. We report 40 
the largest reduction in worry about wasting GP time as a psychosocial barrier to help seeking in the 41 
target deprived group. Our findings may reflect successful strategic targeting of campaign messages 42 
to areas of high socioeconomic deprivation in Wales to modify salient barriers to help seeking.  43 
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Low campaign dose and intensity limited the impact of the Welsh BCOC campaign on health care 1 
activity and clinical outcomes. Additionally, possible contamination from previous English Be Clear 2 
on Cancer lung campaigns into Wales (principally via digital channels) may have potentially diluted 3 
the effect of the Welsh Be Clear on Cancer campaign because people in Wales may have previously 4 
been exposed to campaign messaging. Due to funding constraints, the dedicated Welsh campaign 5 
materials were delivered through fewer outlets and with lower intensity, and the duration of the 6 
campaign was half the dose of the first eight-week English BCOC campaign17,18. Longer campaign 7 
duration, together with a more comprehensive and multi-faceted mode of delivery, may lead to 8 
larger effects, for example the 5-year community based Leeds lung cancer campaign reported an 9 
increase of 80% in chest X-ray referrals19.  10 
The methodological limitations associated with the evaluation of cancer awareness campaigns may 11 
also explain these findings16. Small numbers of new cases during the campaign and comparison 12 
periods hampered effect detection for new/early stage lung cancer diagnoses. Due to funding 13 
limitations and the time-sensitive nature of the project, it is possible that the follow-up period 14 
restricted the capture of changes to clinical outcomes, and is a limitation of the evaluation. A long 15 
follow up period is required to account for the time lag between campaign implementation and 16 
radiology/suspected cancer referral, and to collect clinical data for patients presenting with 17 
symptoms during the campaign who were subsequently diagnosed with lung cancer. Further, data 18 
were obtained from two sources, including Omnibus surveys and routinely collected data records. 19 
Variation in data collection time points precluded direct comparison of data at each time point. 20 
Future campaign evaluations could assess the possible negative effects of the campaign, such as 21 
increased health anxiety. 22 
Promisingly, our findings show that a mass-media cough campaign can increase symptom 23 
awareness, symptomatic presentation and, potentially, GP-ordered diagnostic testing. We found 24 
evidence of reach and reduced barriers to help seeking in socioeconomically deprived groups.  25 
Conclusion 26 
Increased public awareness, cough symptom presentation and GP-ordered diagnostic testing did not 27 
translate into increased USC referrals, new lung cancer diagnoses or stage shift following a national 28 
mass-media lung cancer awareness campaign in Wales. This reflected limitations of campaign 29 
delivery and methodological issues associated with its evaluation. Earlier diagnosis might be 30 
achieved by more intensive, sustained and targeted campaigns, by improving GP diagnostic and 31 
referral systems, and through secondary care pathway redesign. 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
 41 
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